Drug intelligence / Profile preview

HD PepGNP-Dengue

Development stage: Unknown
Lead developer: Gylden Pharma
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

HD PepGNP-Dengue is the high-dose formulation of the candidate vaccine PepGNP-Dengue. It is designed to elicit a specific cytotoxic CD8+ T cell response without inducing a humoral (antibody) response. It is composed of synthetic T cell-selective multi-valent dengue virus (DENV) peptides carried on ultrasmall gold nanoparticles (GNPs). The vaccine is layered with carbohydrates mimicking a bacterial pattern, making it 'self-adjuvanting' and designed to mimic antigen presentation during natural infection. It is administered intradermally to partially mimic a natural mosquito bite infection, target skin antigen-presenting cells, and induce a protective local CD8+ response.

Other names: High Dose PepGNP-Dengue

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on HD PepGNP-Dengue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD PepGNP-Dengue.

Explore the full profile